Klinikum Magdeburg gGmbH
- Address
- lock Available on a paid plan
Digestive System Diseases
At Klinikum Magdeburg gGmbH, researchers are advancing care for cancers of the digestive tract, including stomach, esophagus, colon and rectum. Ongoing studies aim to test innovative drug combinations, refine pre‑operative treatment, and personalize adjuvant therapy based on molecular markers.
- Targeted therapy comparison in metastatic colorectal cancer
- Pre‑operative radiochemotherapy versus chemotherapy for gastroesophageal junction adenocarcinoma
- Adjuvant chemotherapy guided by ctDNA after colon cancer resection
- Combination of niraparib with bevacizumab in advanced ovarian cancer
- Second‑line treatment strategies for esophagogastric adenocarcinoma
With 13 active clinical trials and a team of five investigators, the department contributes to improved outcomes across the spectrum of digestive system malignancies.
Neoplasms
The department’s oncology program focuses on solid tumors such as breast, ovarian and gynecologic cancers, evaluating novel immunotherapies, endocrine agents and targeted drugs to enhance survival.
- Atezolizumab combined with chemotherapy in triple‑negative breast cancer
- Abemaciclib plus endocrine therapy in HR+/HER2‑ early breast cancer
- Elacestrant versus standard endocrine therapy in high‑risk early breast cancer
- Immune‑checkpoint inhibitor plus FLOT in peri‑operative treatment of esophagogastric adenocarcinoma
- Evaluation of ctDNA‑driven adjuvant strategies in colon cancer
These investigations aim to improve disease‑free and event‑free survival, offering patients access to cutting‑edge therapeutic options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Magdeburg gGmbH
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1) | University Of Saarland | Phase III | Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 6 | Unknown | 2016-11-07 | 2025-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.